Par Drugs and ChemicalsNSE:PAR -1.80%74 EBITDA Margin % is 9.18% as of Mar. 2026, which is 54% below its 10-year median of 19.83. GuruFocus rates NSE:PAR with a GF Score™ of 74/100 and a GF Value™ of ₹207.62 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 955 Drug Manufacturers companies, Par Drugs and Chemicals ranks better than 68.69% on this metric.
Par Drugs and Chemicals (NSE:PAR) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Par Drugs and Chemicals EBITDA Margin % Related Terms
Par Drugs and Chemicals EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Par Drugs and Chemicals's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Par Drugs and Chemicals EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Par Drugs and Chemicals's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Par Drugs and Chemicals's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Par Drugs and Chemicals (NSE:PAR) has a EBITDA Margin % of 9.18% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Par Drugs and Chemicals and its competitors. This is 54% below median its historical median of 19.83. Over the past decade, Par Drugs and Chemicals' EBITDA Margin % has ranged from 17.26 to 30.31. According to the industry distribution chart, Par Drugs and Chemicals ranks #299 out of 955 companies in the Drug Manufacturers industry, placing it in the top 31.3%.
Is Par Drugs and Chemicals' EBITDA Margin % too high?
Par Drugs and Chemicals' current EBITDA Margin % of 9.18% is 54% below median its 10-year median of 19.83. Over the past 10 years, this metric has ranged from a low of 17.26 to a high of 30.31. The Drug Manufacturers industry median EBITDA Margin % is 12.44. Par Drugs and Chemicals' value of 9.18% is 26.2% below this industry median. Based on the distribution chart, Par Drugs and Chemicals ranks #299 out of 955 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Par Drugs and Chemicals has a GF Score™ of 74/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Par Drugs and Chemicals' EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Par Drugs and Chemicals ranks #299 out of 955 companies for EBITDA Margin %. This puts Par Drugs and Chemicals in the upper half of its industry. The industry median EBITDA Margin % is 12.44. Par Drugs and Chemicals' value of 9.18% is 26.2% below this benchmark. Historically, Par Drugs and Chemicals' own EBITDA Margin % has ranged from 17.26 to 30.31 over the past decade. While the company's 10-year median is 19.83 vs. the industry median of 12.44, Par Drugs and Chemicals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.44, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Par Drugs and Chemicals's current EBITDA Margin % of 9.18% is 26.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Par Drugs and Chemicals and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Par Drugs and Chemicals's current EBITDA Margin % is 9.18%, which is 54% below median its own 10-year median of 19.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Par Drugs and Chemicals stock overvalued right now?
Based on GuruFocus' analysis, Par Drugs and Chemicals (NSE:PAR) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹207.62, compared to a current price of ₹91.00 — trading 56.2% below its estimated fair value. The current EBITDA Margin % is 9.18%, which is 54% below median its 10-year median of 19.83 and 26.2% below the Drug Manufacturers industry median of 12.44. Par Drugs and Chemicals' overall GF Score™ is 74/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Par Drugs and Chemicals (NSE:PAR), the current EBITDA Margin % is 9.18% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Par Drugs and Chemicals (NSE:PAR) Overvalued in 2026?
Based on GuruFocus' analysis, Par Drugs and Chemicals stock appears to be undervalued.
The current stock price of ₹91.00 is trading 56.2% below its estimated GF Value™ of ₹207.62.
GuruFocus considers Par Drugs and Chemicals to be Significantly Undervalued.
Key valuation signals for NSE:PAR:
EBITDA Margin %: 9.18% (54% below median its 10-year median of 19.83)
GF Value™: ₹207.62 vs. price of ₹91.00 (56.2% below fair value)
Industry Position: 26.2% below the Drug Manufacturers median (#299 of 955)
No single metric tells the full story. See the NSE:PAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Par Drugs and Chemicals Ltd manufactures active Pharmaceutical Ingredients (APIs) and fine chemicals, serving domestic and international markets. Specializing in essential magnesium-based compounds and other specialty chemicals such as Magnesium Hydroxide, Magnesium Trisilicate, Magnesium Carbonate, various grades of Magnesium Oxide, Dried Aluminum Hydroxide Gel, and Sucralfate USP, the Company produces high-quality bulk drugs used in the formulation of finished pharmaceutical products like tablets, capsules, and liquids. Committed to maintaining stringent quality standards and utilizing manufacturing processes, the Company plays a vital role in supplying reliable ingredients that ensure the safety, efficacy, and stability of pharmaceutical formulations internationally.
74GF Score
Get the complete analysis for NSE:PAR
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:PAR has been successfully added to your 
